Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01770145
Other study ID # USWM-AP1-4001
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date December 2012
Est. completion date April 2014

Study information

Verified date October 2017
Source Supernus Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to assess the effect of APOKYN treatment in rapid and reliable improvement of motor symptoms in Parkinson's disease (PD) subjects suffering from delayed or unreliable onset of levodopa (L-dopa) action.


Description:

This Phase IV, Open-Label, Efficacy and Safety Study of APOKYN® is intended to assess the effect of APOKYN treatment in rapid and reliable improvement of motor symptoms in PD subjects suffering from delayed or unreliable onset of L-dopa action. The study will also include a sub-group of 8 subjects to evaluate their gastroparesis and assess their gastric empty with other measures to explore if APOKYN has any influence on gastric empty rather than just bypassing the stomach with a subcutaneous route of administration. The primary objective of this study is to assess the effect of APOKYN treatment in rapid and reliable improvement of motor symptoms in PD subjects suffering from delayed or unreliable onset of L-dopa action (defined below). APOKYN treatment will also be assessed in a sub-group of PD subjects suffering from gastroparesis and delayed onset of L-dopa action. Delayed or unreliable onset to L-dopa for the study population is defined as impaired motor function (tremor, bradykinesia, rigidity, and/or postural instability) persisting for a minimum of 45 minutes after taking a dose of L-dopa because of its delay in onset of action. The impaired motor function resulting from delay in L-dopa onset is referred to as "delayed ON" and when it occurs upon awakening is referred to as "morning akinesia." Main Study: This is a multicenter, multiple-treatment, open-label, outpatient study to evaluate the efficacy and safety of APOKYN in PD subjects with delayed onset of L dopa action. The study will have: - Screening - 1-5 days (Visit 1); - Baseline L-Dopa Period - 7 days, continuation of L dopa treatment; - Antiemetic Treatment Period - 3-days; initiation of trimethobenzamide 300 mg tid orally; - APOKYN Initiation/optimum dose identification Period (Visit 2)- variable, not more than 11 days; - APOKYN Treatment Period - 7 days, immediately upon identification of optimum dose; - Study Discharge (Visit 3)- within 2 days of completion of the APOKYN treatment period. Gastroparesis Sub-Study: A sub-group of subjects (n=8) from 1 study site that have symptoms of gastroparesis will be admitted to the clinic on 2 occasions to undergo gastroparesis procedures and assessments (once at the conclusion of the baseline L-dopa period and once at the conclusion of the APOKYN treatment period). Note, to do the second gastroparesis assessment, this sub-group of subjects will have an extension for one extra day beyond the designated 7 day APOKYN treatment period (i.e., it will be 8 days) in order to keep the 7 day diary recording outpatient scope of work the same as the rest of the subjects in the study. The second inpatient period will be also considered the end-of-study visit for this sub group.


Recruitment information / eligibility

Status Completed
Enrollment 127
Est. completion date April 2014
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female =18 years of age. 2. Idiopathic PD. 3. Not currently taking APOKYN and, if previously prescribed APOKYN, did not discontinue therapy due to intolerable side effects/safety reasons. 4. Prescribed L-dopa therapy at a steady maintenance dose, representing an optimal treatment regimen in the opinion of the Investigator, for at least 4 weeks before study participation. 5. Minimum subject-reported time to turn "on" (TTO) in the early morning (time to end akinetic/ bradykinetic state resulting from delay in L-dopa onset of action) of 45 minutes after the first morning L-dopa dose for a minimum of 3 days/week (as determined with the subject diary at Visit 2). 6. Able to adequately differentiate between and describe variations in "on" and "off" states in the opinion of the Investigator. 7. I to III Modified Hoehn and Yahr stage in the "on" state (Appendix B). 8. Be seeking treatment for early morning akinesia. 9. If female and of childbearing potential, must agree to use one of the following methods of birth control: - Oral contraceptive; - Patch; - Barrier (diaphragm, sponge or condom) plus spermicidal preparations; - Intrauterine contraceptive system; - Levonorgestrel implant; - Medroxyprogesterone acetate contraceptive injection; - Complete abstinence from sexual intercourse; - Hormonal vaginal contraceptive ring; or - Surgical sterilization or partner sterile (must have documented proof). 10. Access to a live-in caregiver, if needed. 11. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study. 12. Able to verbalize understanding of the consent form, able to provide written informed consent. The following must be present for inclusion in the single site gastroparesis sub-study: 13. Have symptoms of gastroparesis. 14. Have improvement of at least one Modified Hoehn and Yahr stage from "off" to "on." 15. Currently seeking treatment for delayed L-dopa onset. 16. Have no allergy to eggs. Exclusion Criteria: 1. Changes in L-dopa dosing regimen 4 weeks before the screening visit. 2. Female who is pregnant or lactating. 3. Contraindications to APOKYN or hypersensitive to apomorphine hydrochloride or any of the ingredients of APOKYN (notably sodium metabisulfite). 4. Participation in any other clinical trial within 14 days of the screening visit. 5. Receipt of any investigational (i.e., unapproved) medication within 30 days of the screening visit. 6. Currently taking, or likely to need to take at any time during the course of the study, any 5HT3 antagonist (i.e., ondansetron, granisetron, dolasetron, palonosetron, alosetron). 7. Currently taking medications for treatment of gastroparesis (e.g., erythromycin, cisapride, metoclopramide). 8. Malignant melanoma or a history of previously treated malignant melanoma within 5 years. 9. Serious medical illness including, but not limited to: - Liver disease; - Kidney problems; and - Heart problems. 10. Psychiatric disorder, including but not limited to dementia or any disorder that, in the opinion of the Investigator requires ongoing treatment that would make study participation unsafe or make treatment compliance difficult. 11. Lack of compliance and follow-up. 12. Any other condition, current therapy, or prior therapy (within 30 days of the screening visit), which, in the opinion of the Investigator, would make the subject unsuitable for the study.

Study Design


Intervention

Drug:
APOKYN
Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' "best on" UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes).
L-dopa
Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
Trimethobenzamide
Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.

Locations

Country Name City State
United States Henry Ford West Bloomfield Hospital Bloomfield Hills Michigan
United States Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton Florida
United States Rush University Medical Center Chicago Illinois
United States University of Cincinnati Academic Health Center Cincinnati Ohio
United States University Hospitals Case Medical Center Cleveland Ohio
United States Parkinson's Disease and Movement Disorders Center of New York Commack New York
United States University of Texas Health Science Center, Houston, Department of Neurology Houston Texas
United States Keck School of Medicine Los Angeles California
United States Neurosearch, Inc. Reseda California
United States Center for Neurological Care and Research San Antonio Texas
United States The Movement Disorder Clinic of Oklahoma Tulsa Oklahoma
United States Georgetown University Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Average Daily "Time to on" ("TTO") by Subject Diary. Patients will record daily "time to on" or "TTO" following their regularly scheduled first L-Dopa dose in the baseline period for 7 consecutive days. Following initiation on Apokyn therapy, patients will inject Apokyn at their regularly scheduled L-Dopa time (L-Dopa dosing will be delayed by 40 minutes following Apokyn injection) and record "time to on" or "TTO" from the injection. "Time to on" for both periods will be recorded in a standardized subject diary. Daily "TTO" for the baseline period will be averaged for each subject and compared to the daily "TTO" for the same subject during the treatment period to assess APOKYN's effect on "TTO". L-Dopa Baseline Days 1-7 and APOKYN Treatment Days 1-7
Secondary Change From Baseline in Gastric Emptying Time A sub-group of subjects from 1 study site that have symptoms of gastroparesis were admitted to the clinic on 2 occasions to undergo gastroparesis procedures and assessments (once at the conclusion of the baseline L-dopa period and once at the conclusion of the APOKYN treatment period). Note, to do the second gastroparesis assessment, this sub-group of subjects had an extension for one extra day beyond the designated 7 day APOKYN treatment period (i.e., it will be 8 days) in order to keep the 7 day diary recording outpatient scope of work the same as the rest of the subjects in the study. The second inpatient period was also considered the end-of-study visit for this sub group. L-Dopa Baseline Days 1-7 and APOKYN Treatment Days 1-8
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Terminated NCT02924194 - Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease N/A
Completed NCT02874274 - Vaccination Uptake (VAX) in PD N/A